US · STIM
Neuronetics, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Malvern, PA 19355
- Website
- neurostar.com
Price · as of 2024-12-31
$2.02
Market cap 91.77M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $24.06 | +1,091.09% |
| Intrinsic Value(DCF) | $465.56 | +22,947.52% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $16.42 | $38.59 | $10.50 | $0.00 | $0.00 |
| 2019 | $2.61 | $20.87 | $1.29 | $0.00 | $0.00 |
| 2020 | $14.71 | $31.50 | $0.00 | $0.00 | $17.98 |
| 2021 | $2.98 | $25.59 | $1.90 | $0.00 | $0.00 |
| 2022 | $3.17 | $24.09 | $0.61 | $0.00 | $0.00 |
| 2023 | $4.12 | $25.37 | $0.01 | $0.00 | $0.00 |
| 2024 | $5.07 | $24.06 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Neuronetics, Inc.'s (STIM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $24.06
- Current price
- $2.02
- AI upside
- +1,091.09%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$465.56
+22,947.52% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| STIM | Neuronetics, Inc. | $2.02 | 91.77M | +1,091% | +22,948% | — | — | -3.68 | 5.81 | 2.15 | -6.51 | -11.71 | -15.27 | 72.32% | -46.15% | -58.36% | -141.29% | -54.52% | -34.06% | 2.98 | -4.74 | 1.86 | 1.41 | -1.84 | 3143.00% | 496.00% | -565.00% | -20.18% | -0.99 | -51.22% | 0.00% | 0.00% | 0.00% | -6.48 | -6.90 | 2.99 | -3.34 |
| ATLN | Atlantic International Co… | $3.15 | 223.78M | +816% | -55% | — | — | -0.97 | -10.93 | 0.30 | -1.89 | -0.19 | -3.02 | 10.66% | -4.93% | -30.61% | 527.46% | -25.40% | -108.64% | -6.88 | -1.82 | 0.91 | 0.76 | -0.73 | 51333.00% | 1027.00% | -3383.00% | -4.61% | -0.06 | -7.05% | 0.00% | 0.00% | 45.10% | -9.77 | -35.22 | 0.48 | 1.97 |
| CDXS | Codexis, Inc. | $1.01 | 91.23M | +2,411% | +12% | — | +481% | -3.17 | 3.09 | 3.49 | -3.31 | — | 3.21 | 72.55% | -98.61% | -109.99% | -85.03% | -128.77% | -45.72% | 0.89 | — | 4.18 | 3.90 | -0.69 | -2054.00% | -1539.00% | -586.00% | -25.95% | -2.09 | -118.20% | 0.00% | 0.00% | 0.00% | -3.31 | -3.60 | 3.26 | -4.07 |
| GNFT | Genfit S.A. | $10.00 | 497.97M | +550% | -76% | -82% | -52% | 103.96 | 2.26 | 2.34 | 16.42 | — | 7.38 | 99.55% | 4.90% | 2.25% | 2.20% | 4.87% | 0.93% | 0.90 | 0.69 | 1.23 | 1.19 | -2.36 | -10517.00% | 13456.00% | -12455.00% | 9.08% | 0.20 | 25.88% | 0.00% | 0.00% | 7.69% | 41.76 | 9.63 | 2.04 | -1.81 |
| NYXH | Nyxoah S.A. | $4.08 | 152.37M | +571% | +9% | — | — | -4.96 | 2.47 | 61.97 | -3.74 | -29.59 | 4.46 | 65.67% | -1300.80% | -1310.24% | -53.42% | -113.83% | -39.94% | 0.20 | -30.90 | 4.56 | 4.13 | 0.20 | 1677.00% | 398.00% | -79.00% | -19.74% | -2.29 | -107.03% | 0.00% | 0.00% | 0.94% | -3.69 | -3.93 | 48.05 | 1.18 |
| OABI | OmniAb, Inc. | $1.72 | 185.11M | +16,336% | +3% | — | +382% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| OSUR | OraSure Technologies, Inc… | $3.15 | 230.38M | +1,022% | -63% | — | +744% | -3164.74 | 0.64 | 1.89 | -3.83 | -1210.05 | 0.64 | 41.90% | -59.23% | -59.76% | -0.02% | -27.37% | -0.02% | 0.00 | — | 6.58 | 0.01 | 0.00 | 26154.00% | -3810.00% | -10023.00% | -0.02% | 0.00 | -0.02% | 0.00% | 0.00% | 6.91% | -3.19 | -4083.36 | 1.89 | 2.48 |
| PRE | Prenetics Global Limited | $16.91 | 237.65M | +204% | +11,114% | — | — | -4.22 | 1.27 | 2.41 | -4.86 | -30.15 | 1.71 | 52.98% | -40.46% | -63.13% | -30.55% | -32.70% | -25.27% | 0.01 | -155.12 | 3.01 | 2.33 | 0.89 | 1401.00% | 20172.00% | -2645.00% | -9.89% | -0.79 | -19.26% | 0.00% | 0.00% | 0.00% | -4.37 | -7.42 | 1.77 | 4.78 |
| PROF | Profound Medical Corp. | $7.61 | 229.84M | +279% | -61% | — | — | -6.11 | 2.81 | 16.71 | -4.69 | — | 2.82 | 65.89% | -309.57% | -260.45% | -60.70% | -267.75% | -48.72% | 0.08 | — | 10.52 | 9.44 | 1.95 | -2074.00% | 4123.00% | 373.00% | -13.80% | -3.57 | -199.52% | 0.00% | 0.00% | 18.51% | -3.82 | -5.12 | 11.81 | 5.24 |
| SGMO | Sangamo Therapeutics, Inc… | $0.43 | 160.68M | +6,900% | -3% | — | +6,207% | -2.14 | 9.21 | 3.63 | -2.23 | — | 9.21 | 100.00% | -179.88% | -169.45% | -185.39% | -403.81% | -73.38% | 1.34 | — | 1.13 | 1.02 | 0.13 | -6689.00% | -6720.00% | -7260.00% | -32.13% | -1.47 | -262.24% | 0.00% | 0.00% | 2.03% | -1.91 | -2.94 | 3.43 | -21.86 |
About Neuronetics, Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
- CEO
- Keith J. Sullivan
- Employees
- 716
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($465.56 ÷ $2.02) − 1 = +22,947.52% (DCF, example).